Patents by Inventor Carl Hay

Carl Hay has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10287362
    Abstract: The present disclosure provides anti-CD73 binding molecules, e.g., antibodies and antigen binding fragments thereof. Also provided are pharmaceutical formulations comprising the disclosed compositions, and methods for the diagnosis and treatment of diseases associated with CD73-expression, e.g., cancer. Such diseases can be treated, e.g., by direct therapy with the anti-CD73 binding molecules disclosed herein (e.g., naked antibodies or antibody-drug conjugates that bind CD73), by adjuvant therapy with other antigen-binding anticancer agents such as immune checkpoint inhibitors (e.g., anti-CTLA-4 and anti-PD-1 monoclonal antibodies), and/or by combination therapies where the anti-CD73 molecules are administered before, after, or concurrently with chemotherapy.
    Type: Grant
    Filed: February 23, 2018
    Date of Patent: May 14, 2019
    Assignee: MedImmune Limited
    Inventors: Carl Hay, Kris Sachsenmeier, Erin Sult, Qihui Huang, Peter Pavlik, Melissa Damschroder, Li Cheng, Gundo Diedrich, Jonathan Rios-Doria, Scott Hammond, Ralph Minter, Steve Rust, Sandrine Guillard, Robert Hollingsworth, Lutz Jermutus, Nicholas Durham, Ching Ching Leow, Mary Antonysamy, James Geoghegan, Xiaojun Lu, Kim Rosenthal
  • Publication number: 20180194858
    Abstract: The present disclosure provides anti-CD73 binding molecules, e.g., antibodies and antigen binding fragments thereof. Also provided are pharmaceutical formulations comprising the disclosed compositions, and methods for the diagnosis and treatment of diseases associated with CD73-expression, e.g., cancer. Such diseases can be treated, e.g., by direct therapy with the anti-CD73 binding molecules disclosed herein (e.g., naked antibodies or antibody-drug conjugates that bind CD73), by adjuvant therapy with other antigen-binding anticancer agents such as immune checkpoint inhibitors (e.g., anti-CTLA-4 and anti-PD-1 monoclonal antibodies), and/or by combination therapies where the anti-CD73 molecules are administered before, after, or concurrently with chemotherapy.
    Type: Application
    Filed: February 23, 2018
    Publication date: July 12, 2018
    Inventors: Carl HAY, Kris SACHSENMEIER, Erin SULT, Qihui Huang, Peter PAVLIK, Melissa DAMSCHRODER, Li CHENG, Gundo DIEDRICH, Jonathan RIOS-DORIA, Scott HAMMOND, Ralph MINTER, Steve RUST, Sandrine GUILLARD, Robert HOLLINGSWORTH, Lutz JERMUTUS, Nicholas DURHAM, Ching Ching LEOW, Mary ANTONYSAMY, James GEOGHEGAN, Xiaojun LU, Kim ROSENTHAL
  • Publication number: 20180125973
    Abstract: The present invention provides therapeutic combinations featuring anti-CD73 antibodies (e.g., MED19447) and A2A receptor inhibitors and methods of using such combinations for reducing tumor-mediated immunosuppression.
    Type: Application
    Filed: September 25, 2017
    Publication date: May 10, 2018
    Applicant: MedImmune Limited
    Inventors: Kris SACHSENMEIER, Erin SULT, Carl HAY, Edmund POON
  • Patent number: 9938356
    Abstract: The present disclosure provides anti-CD73 binding molecules, e.g., antibodies and antigen binding fragments thereof. Also provided are pharmaceutical formulations comprising the disclosed compositions, and methods for the diagnosis and treatment of diseases associated with CD73-expression, e.g., cancer. Such diseases can be treated, e.g., by direct therapy with the anti-CD73 binding molecules disclosed herein (e.g., naked antibodies or antibody-drug conjugates that bind CD73), by adjuvant therapy with other antigen-binding anticancer agents such as immune checkpoint inhibitors (e.g., anti-CTLA-4 and anti-PD-1 monoclonal antibodies), and/or by combination therapies where the anti-CD73 molecules are administered before, after, or concurrently with chemotherapy.
    Type: Grant
    Filed: November 9, 2015
    Date of Patent: April 10, 2018
    Assignee: MEDIMMUNE LIMITED
    Inventors: Carl Hay, Kris Sachsenmeier, Erin Sult, Qihui Huang, Peter Pavlik, Melissa Damschroder, Li Cheng, Gundo Diedrich, Jonathan Rios-Doria, Scott Hammond, Ralph Minter, Steve Rust, Sandrine Guillard, Robert Hollingsworth, Lutz Jermutus, Nicholas Durham, Ching Ching Leow, Mary Antonysamy, James Geoghegan, Xiaojun Lu, Kim Rosenthal
  • Patent number: 9801411
    Abstract: The cigarette smoke-filtering device includes a bottom dome that includes at least one inlet port thereon. The at least one inlet port of the bottom dome is adapted to receive a lit cigarette thereon. The bottom dome is attachable to a top dome. The bottom dome and the top dome form an interior cavity that supports a carbon filter and a smoke chamber. The carbon filter is responsible for filtering cigarette smoke delivered from the lit cigarette via the at least one inlet port. The bottom dome includes an outlet that is affixed to a hose that extends there from. The hose is in turn attached to a mouthpiece.
    Type: Grant
    Filed: January 27, 2015
    Date of Patent: October 31, 2017
    Inventor: Carl Hays
  • Publication number: 20160194407
    Abstract: The present disclosure provides anti-CD73 binding molecules, e.g., antibodies and antigen binding fragments thereof. Also provided are pharmaceutical formulations comprising the disclosed compositions, and methods for the diagnosis and treatment of diseases associated with CD73-expression, e.g., cancer. Such diseases can be treated, e.g., by direct therapy with the anti-CD73 binding molecules disclosed herein (e.g., naked antibodies or antibody-drug conjugates that bind CD73), by adjuvant therapy with other antigen-binding anticancer agents such as immune checkpoint inhibitors (e.g., anti-CTLA-4 and anti-PD-1 monoclonal antibodies), and/or by combination therapies where the anti-CD73 molecules are administered before, after, or concurrently with chemotherapy.
    Type: Application
    Filed: November 9, 2015
    Publication date: July 7, 2016
    Inventors: Carl HAY, Kris Sachsenmeier, Erin Sult, Qihui Huang, Peter Pavlik, Melissa Damschroder, Li Cheng, Gundo Diedrich, Jonathan Rios-Doria, Scott Hammond, Ralph Minter, Steve Rust, Sandrine Guillard, Robert Hollingsworth, Lutz Jermutus, Nicholas Durham, Ching Ching Leow, Mary Antonysamy, James Geoghegan, Xiaojun Lu, Kim Rosenthal
  • Publication number: 20160129108
    Abstract: The present invention provides therapeutic combinations featuring anti-CD73 antibodies (e.g., MEDI9447) and A2A receptor inhibitors and methods of using such combinations for reducing tumor-mediated immunosuppression.
    Type: Application
    Filed: November 10, 2015
    Publication date: May 12, 2016
    Applicant: MedImmune Limited
    Inventors: Kris SACHSENMEIER, Erin Sult, Carl Hay, Edmund Poon
  • Patent number: 8753622
    Abstract: The present invention relates to a novel RNA picornavirus that is called Seneca Valley virus (“SVV”). The invention provides isolated SVV nucleic acids and proteins encoded by these nucleic acids. Further, the invention provides antibodies that are raised against the SVV proteins. Because SVV has the ability to selectively kill some types of tumors, the invention provides methods of using SVV and SVV polypeptides to treat cancer. Because SVV specifically targets certain tumors, the invention provides methods of using SVV nucleic acids and proteins to detect cancer. Additionally, due to the information provided by the tumor-specific mechanisms of SVV, the invention provides methods of making new oncolytic virus derivatives and of altering viruses to have tumor-specific tropisms.
    Type: Grant
    Filed: August 12, 2011
    Date of Patent: June 17, 2014
    Assignee: Novartis AG
    Inventors: Paul Hallenbeck, Seshidhar Reddy Police, Laura M. Hales, Carl Hay, Shanthi Ganesh, Ling Xu, Jingping Yang, Cheng Cheng
  • Publication number: 20130295098
    Abstract: The present invention relates to multispecific epitope binding proteins, methods of making, and uses thereof in the prevention, management, treatment or diagnosis of acute or chronic diseases.
    Type: Application
    Filed: July 5, 2013
    Publication date: November 7, 2013
    Inventors: Herren Wu, Changshou Gao, Carl Hay, Nazzareno Dimasi
  • Patent number: 8039606
    Abstract: The present invention relates to a novel RNA picornavirus that is called Seneca Valley virus (“SVV”). The invention provides isolated SVV nucleic acids and proteins encoded by these nucleic acids. Further, the invention provides antibodies that are raised against the SVV proteins. Because SVV has the ability to selectively kill some types of tumors, the invention provides methods of using SVV and SVV polypeptides to treat cancer. Because SVV specifically targets certain tumors, the invention provides methods of using SVV nucleic acids and proteins to detect cancer. Additionally, due to the information provided by the tumor-specific mechanisms of SVV, the invention provides methods of making new oncolytic virus derivatives and of altering viruses to have tumor-specific tropisms.
    Type: Grant
    Filed: October 9, 2009
    Date of Patent: October 18, 2011
    Assignee: Novartis AG
    Inventors: Paul Hallenbeck, Seshidhar Reddy Police, Laura M. Hales, Carl Hay, Shanthi Ganesh, Ling Xu, Jingping Yang, Cheng Cheng
  • Publication number: 20100233173
    Abstract: The present invention relates to multispecific epitope binding proteins, methods of making, and uses thereof in the prevention, management, treatment or diagnosis of acute or chronic diseases.
    Type: Application
    Filed: March 5, 2010
    Publication date: September 16, 2010
    Applicant: MEDIMMUNE, LLC
    Inventors: Herren WU, Changshou GAO, Carl HAY, Nazzareno DIMASI
  • Publication number: 20090155275
    Abstract: The present invention relates to multispecific epitope binding proteins, methods of making, and uses thereof in the prevention, management, treatment or diagnosis of acute or chronic diseases.
    Type: Application
    Filed: July 30, 2008
    Publication date: June 18, 2009
    Applicant: MEDIMMUNE, LLC
    Inventors: Herren WU, Changshou GAO, Carl HAY, Nazzareno DIMASI
  • Publication number: 20070275915
    Abstract: The present invention generally relates to substances and methods useful for the treatment of neoplastic disease. More specifically, it relates to cancer selective promoters and their use in oncolytic adenoviral vectors. The oncolytic adenoviral vectors are useful in methods of gene therapy. The promoters and the oncolytic adenoviral vectors are useful in methods for screening for compounds that modulate the expression of the cancer selective genes.
    Type: Application
    Filed: April 15, 2004
    Publication date: November 29, 2007
    Inventors: Paul Hallenbeck, Garret Hampton, Carl Hay, Ying Huang, John Jakubczak
  • Publication number: 20070212675
    Abstract: FEN1 transcriptional regulatory sequences (TREs) are provided. FEN1 TREs provide for transcriptional regulation dependent upon transcription factors that are only active in cancer cells. The FEN1 TREs may be used as a vehicle for introducing new genetic capability, particularly associated with cytotoxicity, for selective expression in cancer cells.
    Type: Application
    Filed: April 15, 2004
    Publication date: September 13, 2007
    Applicants: NOVARTIS AG, IRM LLC
    Inventors: Paul Hallenbeck, Garret Hampton, Carl Hay, Ying Huang, John Jakubczak, Sandrina Phipps
  • Publication number: 20060159659
    Abstract: The present invention relates to a novel RNA picornavirus that is called Seneca Valley virus (“SVV”). The invention provides isolated SVV nucleic acids and proteins encoded by these nucleic acids. Further, the invention provides antibodies that are raised against the SVV proteins. Because SVV has the ability to selectively kill some types of tumors, the invention provides methods of using SVV and SVV polypeptides to treat cancer. Because SVV specifically targets certain tumors, the invention provides methods of using SVV nucleic acids and proteins to detect cancer. Additionally, due to the information provided by the tumor-specific mechanisms of SVV, the invention provides methods of making new oncolytic virus derivatives and of altering viruses to have tumor-specific tropisms.
    Type: Application
    Filed: January 19, 2006
    Publication date: July 20, 2006
    Inventors: Paul Hallenbeck, Seshidar Police, Laura Hales, Carl Hay, Shanthi Ganesh, Ling Xu, Jingping Yang, Cheng Cheng